Boston Scientific's heart failure lead:
This article was originally published in Clinica
The Acuity Steerable left ventricular lead developed by Boston Scientific has gained Japanese approval, and may now be used with cardiac resynchronisation therapy (CRT) devices. The lead has a deflectable tip to aid placement in difficult-to-access branch vessels on the left side of the heart. It also provides physicians with four configurations for stimulating the left side of the heart, Boston said, which allows physicians to change the stimulation site noninvasively after implantation. The lead also received reimbursement approval from the Japanese National Health Insurance System. Natick, Massachusetts-based Boston plans to launch the product immediately in Japan.
You may also be interested in...
The regulatory agency also urges qualified persons at drug companies to let the agency know as soon as possible if they are finding that the new measures are not flexible enough to deal with the current logistical challenges quickly.
The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.